For instance, some studies have shown that patients with hereditary cancer predisposition syndromes (e.g., BRCA mutations or TP53 mutations) have a higher risk of developing t-MNs, suggesting that these syndromes may predispose patients to an increased pool of CH mutations, thereby laying the groundwork for subsequent t-MN development (60, 61). The gene discussed is C4B; the disease is therapy-related myeloid neoplasm.